Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Receivables (2020 - 2025)

RxSight (RXST) has disclosed Receivables for 6 consecutive years, with $23.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables fell 22.19% year-over-year to $23.4 million, compared with a TTM value of $23.4 million through Dec 2025, down 22.19%, and an annual FY2025 reading of $23.4 million, down 22.19% over the prior year.
  • Receivables was $23.4 million for Q4 2025 at RxSight, down from $24.2 million in the prior quarter.
  • Across five years, Receivables topped out at $31.0 million in Q1 2025 and bottomed at $3.9 million in Q2 2021.
  • Average Receivables over 5 years is $16.7 million, with a median of $15.2 million recorded in 2023.
  • The sharpest move saw Receivables skyrocketed 125.34% in 2022, then fell 22.19% in 2025.
  • Year by year, Receivables stood at $4.9 million in 2021, then surged by 125.34% to $11.0 million in 2022, then skyrocketed by 85.11% to $20.3 million in 2023, then skyrocketed by 48.17% to $30.0 million in 2024, then fell by 22.19% to $23.4 million in 2025.
  • Business Quant data shows Receivables for RXST at $23.4 million in Q4 2025, $24.2 million in Q3 2025, and $28.1 million in Q2 2025.